PMID- 23879210
OWN - NLM
STAT- MEDLINE
DCOM- 20141208
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 6
IP  - 3
DP  - 2014 May
TI  - Glycemic effects of vildagliptin and metformin combination therapy in Indian 
      patients with type 2 diabetes: an observational study.
PG  - 237-42
LID - 10.1111/1753-0407.12078 [doi]
AB  - BACKGROUND: To analyze the glycemic response of Indian patients with type2 
      diabetes mellitus (T2DM) to combination therapy with vildagliptin and metformin 
      and compare our data with those of clinical trials. METHODS: In a retrospective 
      study of the hospital database, the glycemic control of 280 patients with T2DM 
      who were either on a once- or twice-daily regimen of combination therapy with 
      vildagliptin 50 mg and metformin 500 mg was analyzed. RESULTS: The mean duration 
      of follow-up of the patients was 16.8 months. There was a reduction in fasting 
      plasma glucose (FPG) of 1.52 +/- 0.79 and 1.88 +/- 0.87 mmol/L in the once- and 
      twice-daily groups, respectively (both P < 0.0001) from baseline to last visit. 
      The reduction in postprandial plasma glucose (PPPG) in the once- and twice-daily 
      groups was 3.98 +/- 1.72 and 4.33 +/- 1.88 mmol/L, respectively (both P < 0.0001), 
      whereas the reduction in HbA1c was 1.41 +/- 1.39% and 1.90 +/- 1.49%, respectively 
      (both P < 0.0001). The differences in the reductions achieved in FPG and HbA1c 
      with the two dosing regimens were significant. CONCLUSION: Although the present 
      retrospective study shows a robust response to the combination of vildagliptin 
      and metformin in Indian patients, more multicenter studies from India with a 
      greater number patients are necessary to confirm this finding.
CI  - (c) 2013 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley 
      Publishing Asia Pty Ltd.
FAU - Chatterjee, Sanjay
AU  - Chatterjee S
AD  - Apollo Gleneagles Hospital, Kolkata, India.
FAU - Chatterjee, Sudip
AU  - Chatterjee S
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20130827
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 9100L32L2N (Metformin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/*analogs & derivatives/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Fasting/blood
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Hypoglycemic Agents/therapeutic use
MH  - India/epidemiology
MH  - Metformin/*therapeutic use
MH  - Nitriles/*therapeutic use
MH  - Obesity/epidemiology
MH  - Postprandial Period
MH  - Pyrrolidines/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vildagliptin
OTO - NOTNLM
OT  - India
OT  - combination therapy
OT  - metformin
OT  - type 2 diabetes mellitus
OT  - vildagliptin
OT  - 联合治疗，印度，二甲双胍，2型糖尿病，维格列汀
EDAT- 2013/07/25 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/07/25 06:00
PHST- 2013/03/20 00:00 [received]
PHST- 2013/06/30 00:00 [revised]
PHST- 2013/07/22 00:00 [accepted]
PHST- 2013/07/25 06:00 [entrez]
PHST- 2013/07/25 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1111/1753-0407.12078 [doi]
PST - ppublish
SO  - J Diabetes. 2014 May;6(3):237-42. doi: 10.1111/1753-0407.12078. Epub 2013 Aug 27.